about
[Plasma exchange and immunoadsorption].Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption.Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia.Rapid decrease of serum cholesterol concentration and postpartum depression.Plasma fibronectin and thyroid function.Immunoadsorption for systemic lupus erythematosus.Elevated lipoprotein(a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females?Flow cytometry based detection of HLA alloantibody mediated classical complement activation.Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment.Quantification of coronary artery calcification in patients with FH using EBCT.Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases?Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.Peri-operative immunoadsorption in sensitized renal transplant recipients.Reversible malabsorption caused by high doses of cyclamate.Dose-dependent effect of parenteral iron therapy on bleomycin-detectable iron in immune apheresis patients.Effect of calcium-channel blockers on renal function in renal-graft recipients treated with cyclosporine.Effects of LDL-immunoapheresis on plasma concentrations of vitamin E and carotenoids in patients with familial hypercholesterolemia.Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb).Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients.Effect of combined treatment with immunoadsorption and membrane filtration on plasma coagulation--Results of a randomized controlled crossover study.Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function.Beneficial effect of renal transplantation on cognitive brain function.Signal recognition particle (SRP) positive myositis in a patient with cryptogenic organizing pneumonia (COP).ABO antibody and complement depletion by immunoadsorption combined with membrane filtration--a randomized, controlled, cross-over trial.Variation of lipoprotein(a) plasma levels after premature myocardial infarction.Fibrinogen reduction and bleeding complications in plasma exchange, immunoadsorption and a combination of the two.A case of severe C4d-positive kidney allograft dysfunction in the absence of histomorphologic features of rejection.Extracorporeal artificial liver support in hepatic failure: pathfinder, bridge to recovery or dead end street?Low density lipoprotein immunoapheresis does not increase plasma lipid peroxidation products in vivoUrinary apolipoprotein (a) excretion in patients with proteinuriaLDL-apheresis significantly reduces urinary apo(a) excretionAnti-interleukin-1α autoantibodies in hemodialysis patientsRenal replacement therapy in type 2 diabetic patients: 10 years' experienceDecreased postheparin lipolytic activity in renal transplant recipients with cyclosporin AImpaired conversion of cortisol to cortisone in chronic renal insufficiency--a cause of hypertension or an epiphenomenon?[Qualitative analysis of proteinuria in normal and complicated pregnancy]T-cell selection and T-cell receptor variable beta-chain usage in chronic hemodialysis patientsPredictive value of thallium-201-dipyridamole myocardial stress scintigraphy in chronic hemodialysis patients and transplant recipients[Beta-N-acetylglucosaminidase (beta-NAG) as a parameter in the diagnosis and evaluation of primary glomerular and tubulointerstitial kidney diseases]Accumulation of pneumocystis carinii pneumonia in patients after kidney transplantation
P50
Q33377027-175553BC-9691-42EA-9946-4761BC3779E5Q33982143-36617632-B363-4296-9D78-FB2AD3C39914Q34646746-8DE82C33-7621-4C41-A0A8-1CD8A5917842Q36600086-191A0AC4-32B3-4616-A216-3E2478EDD031Q37188491-39571481-F801-46EE-8B2A-D133783287B2Q37686732-915574E3-5C88-4ADB-B3D6-E4EBD6D18927Q39439221-754F06A7-5943-479D-81A2-89894F5D608DQ40597066-A2530FAE-87E1-4F9C-B16B-65679A4440C4Q40707724-A66450C5-1DFF-43D4-BE54-08F3C7B4F5B7Q43650898-E91E14EA-291D-404F-9A0D-7F71A955498EQ43837879-CB892952-EFC4-42DE-8B5F-93FE304AE98DQ44081450-61AD59E5-C254-43CC-A7EC-EA3FB63054C8Q44082728-49AC6ADE-BEDB-4106-8D4B-963A82864981Q44094914-386D4BD1-CA89-40BC-B6F7-77037ACBE36BQ44939140-4003B380-9101-4885-80B6-B73DD198C9C2Q44982229-5A55D9DF-0EF7-4067-8776-F835DAC1EFB9Q45186205-91597558-625E-4279-BC61-B1FD2E1FA0BFQ45874175-EE9C0AF1-6DA1-4921-A5D1-E5D7B0A04D95Q46399161-75086A2D-3254-48AB-94D6-48D47C672FCBQ47713728-A2CEC39A-D817-4DB9-8279-0FAF8CBCCD45Q47729039-5E0FC8CA-F11B-464C-9E30-D84EC0692E6EQ49099826-E7CB960A-E3C9-4618-8DAC-C35AC75FEFAEQ51623768-27F75C7E-BC3E-4AD1-901E-A5784503AF5AQ51762531-612D63C9-5262-4078-8971-5F4BD88C7ECEQ52956574-21BF8D9A-3BB7-48CA-91EE-A15527DC639EQ53669987-CF27D072-06F5-4C0A-B297-3A407C791B23Q53944635-2F9B7BFD-BE5E-4027-915A-D4C7ACEDCA87Q54027860-B0C82FED-6DE7-4360-93BD-38D27C681917Q58071776-00277B3F-0212-4ED7-AD7E-99789CE344E2Q58071802-69B4D734-84DE-4AF5-8D7A-78672933420CQ58071864-7FCE6BA0-C7CF-4948-905A-CD36DB27BDCEQ61626699-1C5F15A1-5B64-47FA-B037-0BE03B150142Q67601688-7AD69A62-091F-40D1-9E49-C04E2B7519B6Q67766993-1144394F-9905-4898-B596-FD4760496CDFQ67980578-44E026AA-2CD0-4B1E-9403-7D35E08B4F26Q68047926-0DF6C2AE-5DA2-4659-9046-F8328A04CA15Q68057067-45E835DD-D3EC-4ED0-A915-F4BB12D435A2Q68069948-CF4DDD8C-33FE-4A29-9A53-A9E4D195644FQ68075022-56F2055E-BB77-408E-8F63-7B4F94D9657EQ68078689-3460F63B-2565-4794-B5EF-CB6DF4D70582
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kurt Derfler
@ast
Kurt Derfler
@en
Kurt Derfler
@es
Kurt Derfler
@nl
Kurt Derfler
@sl
type
label
Kurt Derfler
@ast
Kurt Derfler
@en
Kurt Derfler
@es
Kurt Derfler
@nl
Kurt Derfler
@sl
prefLabel
Kurt Derfler
@ast
Kurt Derfler
@en
Kurt Derfler
@es
Kurt Derfler
@nl
Kurt Derfler
@sl
P106
P31
P496
0000-0003-2062-7620